Living Cell Technologies

DIABECELL® is LCT's treatment designed to normalize the lives of people with insulin dependent diabetes. DIABECELL® is implanted into patients and works by self-regulating and efficiently secreting insulin in the patient's body.

LCT's encapsulation technology means that this procedure does not require the use of immunosuppressant drugs.

These implanted cells have led to near-normal blood glucose levels in patients, reduced the need for insulin injections and lessened episodes of high blood glucose that lead to long term complications. The treatment is also intended to eliminate life threatening episodes of low blood glucose levels.

LCT has developed a reliable and safe cell source in the form of its bio certified pig herd in New Zealand and also has Good Manufacturing Practice (GMP) accredited manufacturing capabilities in New Zealand. The company has collaborations in Melbourne, Sydney, Auckland, Germany, Italy, Russia and the US.

Website: http://www.lctglobal.com/

The company profiled is one of the investment opportunities currently available in New Zealand. Please note that these opportunities are not endorsed or recommended by New Zealand Trade and Enterprise (NZTE) and may be updated from time to time. Investors are advised to contact our New Zealand-based Investment Specialist to discuss further and to conduct their own due diligence and independent advice on the relevant investment, before committing to any investment.